<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29916" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Telogen Effluvium</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hughes</surname>
            <given-names>Elizabeth C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Syed</surname>
            <given-names>Hasnain A.</given-names>
          </name>
          <aff>Sheikh Zayed Hospital, Lahore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saleh</surname>
            <given-names>Dahlia</given-names>
          </name>
          <aff>Sampson Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Elizabeth Hughes declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hasnain Syed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dahlia Saleh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29916.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Telogen effluvium is a form of nonscarring alopecia&#x000a0;characterized by diffuse, often acute, hair shedding.&#x000a0;Another form that is chronic with a more insidious onset also exists.&#x000a0;Telogen effluvium is the excessive shedding of resting or telogen hair after some metabolic stress, hormonal changes, or medication. Telogen hair is also known as club hair due to the shape of the root. In a normal, healthy individual's scalp, about 85% is anagen hair, and 15% is telogen hair. Anagen hair&#x000a0;is actively growing hair, whereas telogen hair is resting hair. A few hairs may also be in the catagen or transition phase. A hair&#x000a0;follicle typically produces&#x000a0;anagen hair for almost&#x000a0;4 years and then rests for about&#x000a0;4 months. A new anagen hair grows under the resting telogen hair and pushes it out.&#x000a0;Telogen effluvium is a reactive process triggered by metabolic stress, hormonal changes, or medications.</p>
        <p>This activity describes<bold>&#x000a0;</bold>the epidemiology, genetics, clinical presentation, and management of telogen effluvium,&#x000a0;providing healthcare professionals with the knowledge and tools&#x000a0;to identify the condition and improve patient care for this complex and prevalent condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the&#x000a0;characteristic presenting signs and symptoms of telogen effluvium.</p></list-item><list-item><p>Determine underlying causes contributing to telogen effluvium.</p></list-item><list-item><p>Apply the appropriate treatment strategies and support for a patient with telogen effluvium.</p></list-item><list-item><p>Implement interprofessional team strategies for improving care coordination and communication&#x000a0;for&#x000a0;patients&#x000a0;with telogen effluvium.&#x000a0;</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29916&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29916">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29916.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Telogen effluvium is a form of nonscarring alopecia&#x000a0;characterized by diffuse, often acute, hair shedding.<xref ref-type="bibr" rid="article-29916.r1">[1]</xref><xref ref-type="bibr" rid="article-29916.r2">[2]</xref><xref ref-type="bibr" rid="article-29916.r3">[3]</xref><xref ref-type="bibr" rid="article-29916.r4">[4]</xref><xref ref-type="bibr" rid="article-29916.r5">[5]</xref>&#x000a0;Another form that is chronic with a more insidious onset also exists.&#x000a0;Telogen effluvium is the excessive shedding of resting or telogen hair after some metabolic stress, hormonal changes, or medication. Telogen hair is also known as club hair due to the shape of the root. In a normal, healthy individual's scalp, about 85% is anagen hair, and 15% is telogen hair. Anagen hair&#x000a0;is actively growing hair, whereas telogen hair is resting hair. A few hairs may also be in the catagen or transition phase. A hair&#x000a0;follicle typically produces&#x000a0;anagen hair for almost&#x000a0;4 years and then rests for about&#x000a0;4 months. A new anagen hair grows under the resting telogen hair and pushes it out. If the body remains under significant stress, approximately 70% of anagen hair precipitates into the telogen phase, thus causing hair loss.<xref ref-type="bibr" rid="article-29916.r6">[6]</xref></p>
        <p>Telogen effluvium is a reactive process triggered by metabolic stress, hormonal changes, or medications. Common triggering events include acute febrile illness, severe infection, major surgery, severe trauma, postpartum hormonal changes (particularly a decrease in estrogen), hypothyroidism, discontinuing estrogen-containing medication, crash dieting, low protein intake, heavy metal ingestion, and iron deficiency. Many medications have been linked to telogen effluvium, but the most common are beta-blockers and retinoids, including excess vitamin A, anticoagulants, propylthiouracil, carbamazepine, and immunizations.&#x000a0;</p>
      </sec>
      <sec id="article-29916.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Telogen effluvium is a reactive process triggered by metabolic stress, hormonal changes, or medications. Common triggering events include acute febrile illness; severe infection;<xref ref-type="bibr" rid="article-29916.r7">[7]</xref>&#x000a0;major surgery; severe trauma; postpartum hormonal changes,&#x000a0;particularly a decrease in estrogen;&#x000a0;hypothyroidism;<xref ref-type="bibr" rid="article-29916.r8">[8]</xref>&#x000a0;sudden discontinuation&#x000a0;of estrogen-containing medications; crash dieting; low protein intake; heavy metal ingestion; and iron deficiency. Many medications have been linked to telogen effluvium, but the most common are beta-blockers; retinoids, including excess vitamin A; anticoagulants; propylthiouracil; carbamazepine; and immunizations.<xref ref-type="bibr" rid="article-29916.r9">[9]</xref></p>
      </sec>
      <sec id="article-29916.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Telogen effluvium is a condition that can affect individuals of any age, gender, or racial background. The exact prevalence of telogen effluvium is unknown, but it is considered quite common. Many adults experience an episode of telogen effluvium at some point in their lifetime.<xref ref-type="bibr" rid="article-29916.r10">[10]</xref>&#x000a0;Although telogen effluvium can manifest in both men and women, women tend to be more susceptible because of postpartum hormonal changes. In addition, women are more disturbed by hair shedding compared to men and are more likely to seek medical attention.<xref ref-type="bibr" rid="article-29916.r11">[11]</xref><xref ref-type="bibr" rid="article-29916.r12">[12]</xref><xref ref-type="bibr" rid="article-29916.r13">[13]</xref><xref ref-type="bibr" rid="article-29916.r14">[14]</xref></p>
      </sec>
      <sec id="article-29916.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Telogen effluvium is triggered when physiologic stress causes a large number of hairs in the growing phase (anagen phase) of the hair cycle to abruptly enter the resting phase (telogen phase). During this phase, the growth of the telogen hairs ceases for 1 to 6 months (on average 3 months), though the patient does not notice this cessation of growth. When the affected hairs re-enter the growth phase (anagen phase), the hair strands that had been suspended in the resting phase (telogen) are extruded from the follicle, resulting in noticeable hair shedding.</p>
        <p>At a molecular level, etiological factors may disturb the&#x000a0;intricate balance of growth factors, neuroendocrine signals, and cytokine involvement in follicular homeostasis. This disturbance can lead to premature catagen induction or prolongation, accelerating the transition of hairs into the telogen phase.</p>
        <p>Pertinent research in recent years suggests the involvement of inflammatory mediators, oxidative stress, and&#x000a0;changes in the microenvironment of the hair follicle niche in perpetuating telogen effluvium. The involvement of multiple pathways indicates the complexity of telogen effluvium's pathophysiology and provides potential targets for efficient diagnosis and therapeutic intervention.<xref ref-type="bibr" rid="article-29916.r15">[15]</xref></p>
      </sec>
      <sec id="article-29916.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histological findings in telogen effluvium are best observed with&#x000a0;transverse sections of a punch biopsy. The number and density of hair follicles are&#x000a0;typically normal, but there is an&#x000a0;increased percentage of hair follicles in the&#x000a0;catagen or the&#x000a0;telogen phase.<xref ref-type="bibr" rid="article-29916.r15">[15]</xref>&#x000a0;If at least 25% but not more than 50% of the follicles are in the telogen phase, the diagnosis of telogen effluvium is confirmed.</p>
      </sec>
      <sec id="article-29916.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients typically present with hair shedding, usually without other symptoms and with a relatively abrupt onset. By definition,&#x000a0;the shedding in acute telogen effluvium lasts less than&#x000a0;6 months; often, the shedding period is much shorter. Obtaining a thorough history can reveal a causative event (refer to the list in the Etiology section for the conditions that may be considered) occurring approximately 3 months before the onset of the shedding. However, this timeframe could range from 1 to 6 months. Frequently, the patient&#x000a0;may have&#x000a0;completely&#x000a0;recovered from the acute illness or identifiable incident and may not recognize the connection with the hair loss.<xref ref-type="bibr" rid="article-29916.r16">[16]</xref></p>
        <p>The physical examination is grossly normal, as it is difficult for the casual observer to appreciate the volume of hair loss. Comparing the patient's current appearance with old pictures&#x000a0;can be beneficial (see&#x000a0;<bold>Image.&#x000a0;</bold>Telogen Effluvium in a Patient After Prolonged Crash Diet). If the patient presents during the acute shedding, a gentle pull test results in the removal of at least four hairs with each pull. However, if the patient presents after the acute shedding has passed, the pull test may yield normal results. A thorough examination of the scalp may&#x000a0;reveal an increased percentage of short anagen hairs growing close to the scalp, and no scarring should be evident.</p>
      </sec>
      <sec id="article-29916.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Typically, obtaining a&#x000a0;detailed&#x000a0;history and performing a thorough physical examination&#x000a0;are sufficient for diagnosing&#x000a0;telogen effluvium. If a biopsy is performed during the acute shedding phase (when the pull test is positive), it can confirm an increase in the percentage of telogen hairs.<xref ref-type="bibr" rid="article-29916.r15">[15]</xref>&#x000a0;Testing for underlying hormonal conditions, such as hypothyroidism; chronic metabolic illnesses; or iron deficiency is recommended if there are concerns about these conditions.<xref ref-type="bibr" rid="article-29916.r17">[17]</xref><xref ref-type="bibr" rid="article-29916.r18">[18]</xref></p>
        <p>
<bold>Laboratory Testing</bold>
</p>
        <p>
<bold>Hypothyroidism</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypothyroidism can lead to chronic telogen effluvium.</p>
          </list-item>
          <list-item>
            <p>When symptoms of hypothyroidism, such as tiredness, constipation, weight gain, and cold sensitivity, are present, a thyrotropin test is warranted.<xref ref-type="bibr" rid="article-29916.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Iron deficiency</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Iron deficiency should be evaluated with a complete blood count, serum iron, iron saturation, and ferritin.&#x000a0;<xref ref-type="bibr" rid="article-29916.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Given the priority of blood for survival over hair, the body prioritizes shedding hair before red blood cell indices become microcytic.</p>
          </list-item>
          <list-item>
            <p>Ferritin acts as an acute-phase reactant, and inflammation can result in normal ferritin levels in an iron-deficient individual.</p>
          </list-item>
          <list-item>
            <p>Low ferritin confirms iron deficiency; a normal ferritin level does not exclude iron deficiency.</p>
          </list-item>
          <list-item>
            <p>Iron saturation is the most sensitive indicator of iron deficiency.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Syphilis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>When symptoms of syphilis, such as fatigue, patchy hair loss, sore throat, or swollen lymph nodes, are present and considered a cause, a rapid plasma reagin or venereal disease research&#x000a0;laboratory&#x000a0;(VDRL) test should be performed.</p>
          </list-item>
        </list>
        <p>
<bold>Biopsy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Scalp biopsy is the most useful test to confirm the diagnosis,&#x000a0;but it is seldom necessary&#x000a0;if gentle hair pull produces&#x000a0;numerous&#x000a0;telogen hairs.</p>
          </list-item>
          <list-item>
            <p>A white bulb and no gelatinous hair sheath can identify telogen hair.</p>
          </list-item>
          <list-item>
            <p>If a patient is unwilling to allow a scalp biopsy, serial hair collections can&#x000a0;be obtained.</p>
          </list-item>
          <list-item>
            <p>The patient should be instructed to collect all shedding hair in 24 hours, refraining from washing their hair during this time. This process should be repeated every week for three or four collections.</p>
          </list-item>
          <list-item>
            <p>Collecting 100 or more hairs in 24 hours suggests telogen effluvium. The number of hairs collected may decrease if the collections are performed over several weeks while the telogen effluvium improves.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29916.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Acute telogen effluvium is a self-limited condition. If the causative event&#x000a0;has been identified and appropriately treated, there is no need for further treatment. If a hormonal&#x000a0;or dietary imbalance, such as low iron levels, zinc levels, vitamin D levels; or metabolic illness is present, hair growth returns after these factors are corrected.<xref ref-type="bibr" rid="article-29916.r21">[21]</xref>&#x000a0;If a medication is the cause of the shedding, hair growth restarts after the medication is withdrawn.<xref ref-type="bibr" rid="article-29916.r22">[22]</xref></p>
        <p>Although&#x000a0;topical minoxidil has not been proven to promote hair recovery in telogen effluvium, it has theoretical benefits. Patients who wish to take an active role in their treatment may choose to use topical minoxidil. Recent trials have&#x000a0;proven that oral minoxidil can be an effective and well-tolerated treatment alternative for healthy patients with difficulty with topical formulations.<xref ref-type="bibr" rid="article-29916.r23">[23]</xref></p>
        <p>Recent studies have also shown that both botulinum toxin A and multivitamin mesotherapy are effective in treating telogen effluvium. These treatments demonstrated improvement of the criteria&#x000a0;terminal hair and multiple follicular units.<xref ref-type="bibr" rid="article-29916.r24">[24]</xref>&#x000a0;</p>
        <p>Most importantly, all the patients should be offered emotional support and reassurance about the benign course of the disease and the possibility of complete recovery of hair with time and nutritional support.&#x000a0;</p>
      </sec>
      <sec id="article-29916.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses of telogen effluvium include alopecia areata, anagen effluvium, androgenetic alopecia, scarring alopecia, syphilis, and trichotillomania.</p>
      </sec>
      <sec id="article-29916.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Morbidity associated with telogen effluvium is typically limited to mild cosmetic changes, and there have been no reports of mortality.</p>
        <list list-type="bullet">
          <list-item>
            <p>Telogen effluvium has a significant psychological impact on individuals affected by the disease, and therefore, counseling is required.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The prognosis for a good recovery of hair density occurs in acute telogen effluvium.</p>
          </list-item>
          <list-item>
            <p>A good cosmetic outcome is also expected in chronic telogen effluvium, even if the hair shedding continues.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29916.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Telogen effluvium is a benign and spontaneously reversible condition with no associated complications. As it is a non-cicatricial alopecia, the scalp has no scarring, even during the active hair loss phase.</p>
      </sec>
      <sec id="article-29916.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Hair growth may take up to&#x000a0;6 months to restart and even longer for the growth to be appreciated by the patient. Patients often require the reassurance of the normal recovery of their hair while the hair re-enters the anagen phase and grows normally. Patients may also worry that normal grooming of their hair worsens hair shedding. Patients should be reassured that their hair is normal and they can continue to wash and style it as usual.</p>
      </sec>
      <sec id="article-29916.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The diagnosis and management of hair loss involve an interprofessional team comprising a dermatologist, primary care provider, nurse practitioner, and internist. Telogen effluvium is a type of nonscarring alopecia characterized by diffuse and often acute hair shedding. In most cases, no specific cause is identified. In any case, patients should be informed that the condition is self-limiting. Prescribing hair growth medications or referring patients for hair transplants is unnecessary. Although hair growth may take several months to a year to fully restore, the outcome is generally favorable for most patients.<xref ref-type="bibr" rid="article-29916.r25">[25]</xref><xref ref-type="bibr" rid="article-29916.r26">[26]</xref></p>
      </sec>
      <sec id="article-29916.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29916&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29916">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/telogen-effluvium/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=29916">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29916/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29916">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-29916.s16">
        <fig id="article-29916.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Telogen Effluvium in a Patient After Prolonged Crash Diet. The image shows the patient's scalp with hair loss resulting from prolonged crash dieting. Contributed by Hasnain Ali Syed, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMG_2928" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-29916.s17">
        <title>References</title>
        <ref id="article-29916.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nistico</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tamburi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bennardo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dastoli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schipani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Caro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fortuna</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Treatment of telogen effluvium using a dietary supplement containing Boswellia serrata, Curcuma longa, and Vitis vinifera: Results of an observational study.</article-title>
            <source>Dermatol Ther</source>
            <year>2019</year>
            <month>May</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>e12842</fpage>
            <pub-id pub-id-type="pmid">30693615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sari Aslani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Heidari Esfahani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sepaskhah</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Non-scarring Alopecias in Iranian Patients: A Histopathological Study With Hair Counts.</article-title>
            <source>Iran J Pathol</source>
            <year>2018</year>
            <season>Summer</season>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-324</page-range>
            <pub-id pub-id-type="pmid">30636954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sahin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pancar</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Kalkan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>New pattern hair loss in young Turkish women; What's wrong in their daily life?</article-title>
            <source>Skin Res Technol</source>
            <year>2019</year>
            <month>May</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>367</fpage>
            <page-range>367-374</page-range>
            <pub-id pub-id-type="pmid">30614076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stoehr</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Colavincenzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vanderweil</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Off-Label Use of Topical Minoxidil in Alopecia: A Review.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>237</fpage>
            <page-range>237-250</page-range>
            <pub-id pub-id-type="pmid">30604379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daly</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Telogen Effluvium With Dysesthesia (TED) Has Lower B12 Levels and May Respond to B12 Supplementation.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2018</year>
            <month>Nov</month>
            <day>01</day>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>1236</fpage>
            <page-range>1236-1240</page-range>
            <pub-id pub-id-type="pmid">30500148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asghar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shamim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Farooque</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aqeel</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Telogen Effluvium: A Review of the Literature.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>May</month>
            <day>27</day>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>e8320</fpage>
            <pub-id pub-id-type="pmid">32607303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Te&#x00161;anovi&#x00107; Perkovi&#x00107;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vukojevi&#x00107;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bukvi&#x00107; Mokos</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Post-COVID Telogen Effluvium.</article-title>
            <source>Acta Dermatovenerol Croat</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>220</fpage>
            <page-range>220-226</page-range>
            <pub-id pub-id-type="pmid">36919388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bin Dayel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hussein</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Atia</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Abahussein</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Al Yahya</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Elsayed</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Is thyroid dysfunction a common cause of telogen effluvium?: A retrospective study.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2024</year>
            <month>Jan</month>
            <day>05</day>
            <volume>103</volume>
            <issue>1</issue>
            <fpage>e36803</fpage>
            <pub-id pub-id-type="pmid">38181279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>LaSenna</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>BE</given-names>
              </name>
            </person-group>
            <article-title>Culprits of Medication-Induced Telogen Effluvium, Part 1.</article-title>
            <source>Cutis</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>112</volume>
            <issue>6</issue>
            <fpage>267</fpage>
            <page-range>267-271</page-range>
            <pub-id pub-id-type="pmid">38290075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seyfi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alijanpour</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Aryanian</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ezoji</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mahmoudi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity.</article-title>
            <source>J Med Life</source>
            <year>2022</year>
            <month>May</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>631</fpage>
            <page-range>631-634</page-range>
            <pub-id pub-id-type="pmid">35815081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sant'Anna Addor</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Donato</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Melo</surname>
                <given-names>CSA</given-names>
              </name>
            </person-group>
            <article-title>Comparative evaluation between two nutritional supplements in the improvement of telogen effluvium.</article-title>
            <source>Clin Cosmet Investig Dermatol</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>431</fpage>
            <page-range>431-436</page-range>
            <pub-id pub-id-type="pmid">30237729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Udompanich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chanprapaph</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suchonwanit</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hair and Scalp Changes in Cutaneous and Systemic Lupus Erythematosus.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>679</fpage>
            <page-range>679-694</page-range>
            <pub-id pub-id-type="pmid">29948959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Saleh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nassereddin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saleh</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <chapter-title>Anagen Effluvium</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>4</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">29493918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Motosko</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Bieber</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Pomeranz</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Martires</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Physiologic changes of pregnancy: A review of the literature.</article-title>
            <source>Int J Womens Dermatol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>219</fpage>
            <page-range>219-224</page-range>
            <pub-id pub-id-type="pmid">29234716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yorulmaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hayran</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ozdemir</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Genc</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gur Aksoy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yalcin</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Telogen effluvium in daily practice: Patient characteristics, laboratory parameters, and treatment modalities of 3028 patients with telogen effluvium.</article-title>
            <source>J Cosmet Dermatol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>2610</fpage>
            <page-range>2610-2617</page-range>
            <pub-id pub-id-type="pmid">34449961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jimeno Ortega</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Stefanato</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Telogen effluvium: a 360 degree review.</article-title>
            <source>Ital J Dermatol Venerol</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>158</volume>
            <issue>6</issue>
            <fpage>457</fpage>
            <page-range>457-466</page-range>
            <pub-id pub-id-type="pmid">38015483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirallas</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Grimalt</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The Postpartum Telogen Effluvium Fallacy.</article-title>
            <source>Skin Appendage Disord</source>
            <year>2016</year>
            <month>May</month>
            <volume>1</volume>
            <issue>4</issue>
            <fpage>198</fpage>
            <page-range>198-201</page-range>
            <pub-id pub-id-type="pmid">27386466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malkud</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Telogen Effluvium: A Review.</article-title>
            <source>J Clin Diagn Res</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>WE01</fpage>
            <page-range>WE01-3</page-range>
            <pub-id pub-id-type="pmid">26500992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kakpovbia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ogbechie-Godec</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lo Sicco</surname>
                <given-names>KI</given-names>
              </name>
            </person-group>
            <article-title>Laboratory Testing in Telogen Effluvium.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2021</year>
            <month>Jan</month>
            <day>01</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>110</fpage>
            <page-range>110-111</page-range>
            <pub-id pub-id-type="pmid">33400415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x00130;bi&#x0015f;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aksoy Sara&#x000e7;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Akda&#x0011f;</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of MCV/RDW Ratio and Correlations With Ferritin in Telogen Effluvium Patients.</article-title>
            <source>Dermatol Pract Concept</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>e2022151</fpage>
            <pub-id pub-id-type="pmid">36159144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saini</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mysore</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Role of vitamin D in hair loss: A short review.</article-title>
            <source>J Cosmet Dermatol</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>20</volume>
            <issue>11</issue>
            <fpage>3407</fpage>
            <page-range>3407-3414</page-range>
            <pub-id pub-id-type="pmid">34553483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mysore</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Parthasaradhi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kharkar</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Ghoshal</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Ganjoo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ravichandran</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saraswat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Remadevi</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Matte</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Expert consensus on the management of Telogen Effluvium in India.</article-title>
            <source>Int J Trichology</source>
            <year>2019</year>
            <season>May-Jun</season>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>107</fpage>
            <page-range>107-112</page-range>
            <pub-id pub-id-type="pmid">31360038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Randolph</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tosti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Oral minoxidil treatment for hair loss: A review of efficacy and safety.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>737</fpage>
            <page-range>737-746</page-range>
            <pub-id pub-id-type="pmid">32622136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khattab</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Rady</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khashaba</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Recent modalities in treatment of telogen effluvium: Comparative study.</article-title>
            <source>Dermatol Ther</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>35</volume>
            <issue>10</issue>
            <fpage>e15720</fpage>
            <pub-id pub-id-type="pmid">35851518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mubki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rudnicka</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Olszewska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and diagnosis of the hair loss patient: part I. History and clinical examination.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>415.e1</fpage>
            <page-range>415.e1-415.e15</page-range>
            <pub-id pub-id-type="pmid">25128118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29916.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamm</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Acquired alopecia in childhood].</article-title>
            <source>Hautarzt</source>
            <year>2013</year>
            <month>May</month>
            <volume>64</volume>
            <issue>5</issue>
            <fpage>371</fpage>
            <page-range>371-9; quiz 380-1</page-range>
            <pub-id pub-id-type="pmid">23571647</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
